Search Results - "The Lancet infectious diseases"
-
1
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Published in The Lancet infectious diseases (01-06-2020)“…In the face of rapidly changing data, a range of case fatality ratio estimates for coronavirus disease 2019 (COVID-19) have been produced that differ…”
Get full text
Journal Article -
2
Early dynamics of transmission and control of COVID-19: a mathematical modelling study
Published in The Lancet infectious diseases (01-05-2020)“…An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to 95 333 confirmed cases as of March 5, 2020. Understanding the early…”
Get full text
Journal Article -
3
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Published in The Lancet infectious diseases (01-02-2021)“…With the unprecedented morbidity and mortality associated with the COVID-19 pandemic, a vaccine against COVID-19 is urgently needed. We investigated CoronaVac…”
Get full text
Journal Article -
4
Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study
Published in The Lancet infectious diseases (01-08-2020)“…Rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China, prompted heightened surveillance in Shenzhen, China. The…”
Get full text
Journal Article -
5
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study
Published in The Lancet infectious diseases (01-01-2022)“…The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March, 2021. It has since rapidly become the predominant lineage, owing to high…”
Get full text
Journal Article -
6
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
Published in The Lancet infectious diseases (01-07-2021)“…The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials. We…”
Get full text
Journal Article -
7
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
Published in The Lancet infectious diseases (01-01-2021)“…The ongoing COVID-19 pandemic warrants accelerated efforts to test vaccine candidates. We aimed to assess the safety and immunogenicity of an inactivated…”
Get full text
Journal Article -
8
Viral dynamics in mild and severe cases of COVID-19
Published in The Lancet infectious diseases (01-06-2020)“…Patients who had any of the following features at the time of, or after, admission were classified as severe cases: (1) respiratory distress (≥30 breaths per…”
Get full text
Journal Article -
9
Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study
Published in The Lancet infectious diseases (01-02-2022)“…The SARS-CoV-2 delta (B.1.617.2) variant is highly transmissible and spreading globally, including in populations with high vaccination rates. We aimed to…”
Get full text
Journal Article -
10
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study
Published in The Lancet infectious diseases (01-01-2022)“…COVID-19 vaccines show excellent efficacy in clinical trials and effectiveness in real-world data, but some people still become infected with SARS-CoV-2 after…”
Get full text
Journal Article -
11
Real estimates of mortality following COVID-19 infection
Published in The Lancet infectious diseases (01-07-2020)Get full text
Journal Article -
12
Clinical and virological data of the first cases of COVID-19 in Europe: a case series
Published in The Lancet infectious diseases (01-06-2020)“…On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named…”
Get full text
Journal Article -
13
Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study
Published in The Lancet infectious diseases (01-11-2020)“…Within 4 months of COVID-19 first being reported in the USA, it spread to every state and to more than 90% of all counties. During this period, the US COVID-19…”
Get full text
Journal Article -
14
Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study
Published in The Lancet infectious diseases (01-10-2020)“…The isolation of symptomatic cases and tracing of contacts has been used as an early COVID-19 containment measure in many countries, with additional physical…”
Get full text
Journal Article -
15
COVID-19: combining antiviral and anti-inflammatory treatments
Published in The Lancet infectious diseases (01-04-2020)“…Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for…”
Get full text
Journal Article -
16
The value of antimicrobial peptides in the age of resistance
Published in The Lancet infectious diseases (01-09-2020)“…Accelerating growth and global expansion of antimicrobial resistance has deepened the need for discovery of novel antimicrobial agents. Antimicrobial peptides…”
Get full text
Journal Article -
17
Genomic evidence for reinfection with SARS-CoV-2: a case study
Published in The Lancet infectious diseases (01-01-2021)“…The degree of protective immunity conferred by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently unknown. As such, the…”
Get full text
Journal Article -
18
Convalescent plasma as a potential therapy for COVID-19
Published in The Lancet infectious diseases (01-04-2020)Get full text
Journal Article -
19
Can we contain the COVID-19 outbreak with the same measures as for SARS?
Published in The Lancet infectious diseases (01-05-2020)“…The severe acute respiratory syndrome (SARS) outbreak in 2003 resulted in more than 8000 cases and 800 deaths. SARS was eventually contained by means of…”
Get full text
Journal Article -
20
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Published in The Lancet infectious diseases (01-02-2021)“…The novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused more than 1 million deaths in the first 6 months of the…”
Get full text
Journal Article